Blueprint Medicines (NASDAQ:BPMC) Issues Earnings Results

Blueprint Medicines (NASDAQ:BPMC) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11), Zacks reports. Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%.

Blueprint Medicines Trading Up 2.1 %

NASDAQ:BPMC traded up $2.01 during midday trading on Thursday, hitting $96.08. 188,518 shares of the company traded hands, compared to its average volume of 1,014,469. The firm’s fifty day moving average is $99.53 and its 200-day moving average is $94.40. Blueprint Medicines has a 12-month low of $80.42 and a 12-month high of $121.90. The firm has a market capitalization of $6.14 billion, a P/E ratio of -88.99 and a beta of 0.62. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15.

Wall Street Analyst Weigh In

BPMC has been the subject of a number of research analyst reports. Wedbush reiterated an “outperform” rating and issued a $128.00 target price (up previously from $124.00) on shares of Blueprint Medicines in a research report on Thursday, February 13th. Needham & Company LLC reiterated a “buy” rating and issued a $133.00 target price on shares of Blueprint Medicines in a research note on Thursday, February 13th. Guggenheim reiterated a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. JMP Securities reiterated a “market outperform” rating and issued a $125.00 target price on shares of Blueprint Medicines in a research note on Friday, February 14th. Finally, Piper Sandler raised their target price on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $123.83.

Insider Activity at Blueprint Medicines

In related news, COO Christina Rossi sold 2,274 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $95.10, for a total transaction of $216,257.40. Following the sale, the chief operating officer now owns 71,657 shares in the company, valued at approximately $6,814,580.70. This represents a 3.08 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Kate Haviland sold 2,353 shares of the company’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $96.60, for a total value of $227,299.80. Following the completion of the transaction, the chief executive officer now directly owns 150,824 shares in the company, valued at $14,569,598.40. This trade represents a 1.54 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 49,851 shares of company stock worth $4,984,696. Company insiders own 4.21% of the company’s stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.